In Cartilage Repair Histogenics Resets The Stage
This article was originally published in Start Up
Executive Summary
In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.
You may also be interested in...
Failed Phase III For NeoCart May Still Fly With US FDA, Histogenics Argues
Agency guidance does not require coprimary, dual responder endpoint for drugs developed for knee cartilage repair, so in Histogenics' view, door is still open for approval.
Progress In Cartilage Repair: The Holy Grail Of Knee OA
Researchers have been working for years to develop a reliable and cost-effective means of regenerating the hyaline cartilage found in the knee, with the aim of offering a minimally invasive treatment option for the millions of patients with painful knee osteoarthritis. Although this goal has been elusive so far, recent progress suggests the field may have turned a corner, and a large number of companies are now competing to win this quest, which many refer to as the “Holy Grail” of knee OA.
Medtech’s Share Of Private Investment Dollars In 2012
Each year, START-UP reviews the sectors of the medical device industry that received private funding to see what will be filling the pipelines of medical device companies in the future. Despite gloomy talk by VCs and strategics predicting a future scarcity of new innovative products, the actual data from 2012 show many categories holding steady and pockets of up-and-coming technologies attracting investment.